APA

Eigl B. J., North S., Winquist E., Finch D., Wood L., Sridhar S. S., Powers J., Good J., Sharma M., Squire J. A., Bazov J., Jamaspishvili T., Cox M. E., Bradbury P. A., Eisenhauer E. A. & Chi K. N. (20160512). A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. : Investigational new drugs.

Chicago

Eigl B J, North S, Winquist E, Finch D, Wood L, Sridhar S S, Powers J, Good J, Sharma M, Squire J A, Bazov J, Jamaspishvili T, Cox M E, Bradbury P A, Eisenhauer E A and Chi K N. 20160512. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. : Investigational new drugs.

Harvard

Eigl B. J., North S., Winquist E., Finch D., Wood L., Sridhar S. S., Powers J., Good J., Sharma M., Squire J. A., Bazov J., Jamaspishvili T., Cox M. E., Bradbury P. A., Eisenhauer E. A. and Chi K. N. (20160512). A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. : Investigational new drugs.

MLA

Eigl B J, North S, Winquist E, Finch D, Wood L, Sridhar S S, Powers J, Good J, Sharma M, Squire J A, Bazov J, Jamaspishvili T, Cox M E, Bradbury P A, Eisenhauer E A and Chi K N. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. : Investigational new drugs. 20160512.